Similarly, IGF2BP3 overexpression de-sensitized sorafenib and doxorubicin by enhancing cancer stem cell marker CD133 and drug efflux proteins such as ABCB1 and ABCG2 in human hepatocellular carcinoma. Here, IGF2BP3 is linked to cancer.